Trevi Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TRVI and other ETFs, options, and stocks.About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease.
CEOJennifer L. Good
CEOJennifer L. Good
Employees26
Employees26
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2011
Founded2011
Employees26
Employees26
TRVI Key Statistics
Market cap641.47M
Market cap641.47M
Price-Earnings ratio-13.76
Price-Earnings ratio-13.76
Dividend yield—
Dividend yield—
Average volume7.81M
Average volume7.81M
High today$6.93
High today$6.93
Low today$6.37
Low today$6.37
Open price$6.52
Open price$6.52
Volume3.19M
Volume3.19M
52 Week high$7.39
52 Week high$7.39
52 Week low$2.30
52 Week low$2.30
TRVI News
TipRanks 3d
Trevi Therapeutics Stock Surges Over 60% on Promising Trial Results and Q4 FinancialsTrevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The strong upswing h...
TipRanks 3d
Trevi Therapeutics’ Promising Prospects: Buy Rating Backed by Positive Trial Results and Market PotentialAnalyst Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) and decreased the price target to $24.00 from $25.00....
TipRanks 3d
Trevi Therapeutics’ Haduvio: Promising Developments and Strategic Advancements Reinforce Buy RatingOren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Trevi Therapeutics (TRVI – Research Report). The associated price target remains the...
Analyst ratings
100%
of 11 ratingsBuy
100%
Hold
0%
Sell
0%